61058-42-2

Basic information

• Product Name: Glycine, N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-, methyl ester
• Synonyms: N-(1-benzyloxycarbonyl-L-prolyl)-glycine methyl ester;N-(1-Benzyloxycarbonyl-L-prolyl)-glycin-methylester;Z-Pro-Gly-OMe;Cbz-Pro-Gly-OMe
• CAS NO: 61058-42-2
• Molecular Formula: C16H20N2O5
• Molecular Weight: 320.345
• Mol File: 61058-42-2.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Glycine, N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Glycine, N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-, methyl ester(61058-42-2)
• EPA Substance Registry System: Glycine, N-[1-[(phenylmethoxy)carbonyl]-L-prolyl]-, methyl ester(61058-42-2)

Safety Data

• Hazardous Substances Data: 61058-42-2(Hazardous Substances Data)

Upstream product

• 5680-79-5 glycine ethyl ester hydrochloride 
• 3304-59-4 N-benzyloxycarbonyl-L-proline p-nitrophenyl ester 
• 616-34-2 methoxycarbonylmethylamine 
• 501-53-1 benzyl chloroformate 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 67-56-1 methanol 
• 35010-96-9 Nα-benzyloxycarbonyl-L-prolyl-glycinamide 
• 147-85-3 L-proline 
• 26607-48-7 1-benzyl hydrogen (S)-pyrrolidine-1,2-dicarboxylate, compound with dicyclohexylamine (1:1) 
• 541-41-3 chloroformic acid ethyl ester 

Downstream Products

• 131697-41-1 Z-Asn-Pro-Gly-OMe 
• 131697-42-2 Boc-Tyr-Asn-Pro-Gly-OMe 
• 131696-84-9 H-Tyr-Asn-Pro-Gly-OMe*HCl 
• 1319113-23-9 Cbz-L-Pro-Gly(OMe)-OMe 
• 37700-65-5 N-benzyloxycarbonyl-prolyl-glycylglycine 
• 2766-18-9 N-carbobenzoxyprolylglycine 
• 134053-86-4 (3S,6S)-3-methoxy-1,6-trimethylene-2,5-piperazinedione 
• 97985-95-0 {(S)-1-[(S)-1-{[((S)-1-{(S)-1-[(S)-2-(Carbamoylmethyl-carbamoyl)-pyrrolidine-1-carbonyl]-4-guanidino-butylcarbamoyl}-3-methyl-butylcarbamoyl)-methyl]-carbamoyl}-2-(4-hydroxy-phenyl)-ethylcarbamoyl]-2-hydroxy-ethyl}-carbamic acid benzyl ester 
• 97985-97-2 amide of benzyloxycarbonylarginylprolylglycine 
• 51776-33-1 luteinizing hormone-releasing hormone (4-10) 
• 132478-01-4 (S)-1-[(S)-2-((S)-2-{(R)-2-[(S)-2-((S)-2-Amino-3-hydroxy-propionylamino)-3-(4-hydroxy-phenyl)-propionylamino]-3-phenyl-propionylamino}-4-methyl-pentanoylamino)-5-guanidino-pentanoyl]-pyrrolidine-2-carboxylic acid carbamoylmethyl-amide 
• 77659-17-7 Z-Pro-Ser-Tyr-D-Ala-Leu-(O₂N)Arg-Pro-Gly-NH₂ 
• 77659-12-2 Z-D-Ala-Leu-(O₂N)Arg-Pro-Gly-NH₂ 
• 41271-84-5 Z-Leu-(O₂N)Arg-Pro-Gly-NH₂ 

Relevant articles and documents

Organocatalyzed Asymmetric Aldol Reaction of α-Keto Amides with A Tripeptide Catalyst

An organocatalyzed asymmetric aldol reaction of α-keto amides was developed. An N-terminal 4- trans -siloxyproline-based tripeptide with an l - tert -leucine unit adjacent to the 4- trans -siloxyproline residue was used to catalyze the reaction between various α-keto amides and acetone, to produce the corresponding aldol adducts with up to 99% yield and 91% ee.

Borinic acid catalysed peptide synthesis

The catalytic synthesis of peptides is a major challenge in the modern organic chemistry hindered by the well-established use of stoichiometric coupling reagents. Herein, we describe for the first time that borinic acid is able to catalyse this reaction under mild conditions with an improved activity compared to our recently developed thiophene-based boronic acid. This catalyst is particularly efficient for peptide bond synthesis affording dipeptides in good yields without detectable racemization.

PYRIMIDINE DERIVATIVE

This invention provides pyrimidine derivatives represented by a formula, in the formula, ring A stands for carbocyclic group or heterocyclic group, X 1 stands for hydrogen, lower alkyl, amino, etc., X 2 stands for hydrogen or lower alkyl, Y stands for a direct bond or sulfur or nitrogen, n stands for an integer of 0 - 4, and Ar stands for a group of the following formula, or a salt thereof, which concurrently exhibit 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity and are useful for therapy and treatments of diseases such as IBS. The invention furthermore provides a therapeutic method of IBS, characterized by having 5-HT 1A agonistic activity and 5-HT 3 antagonistic activity work simultaneously and cooperatively in vivo, which comprises either administering 5-HT 3 antagonistic agent which concurrently exhibits 5-HT 1A agonistic activity, or administering 5-HT 1A agonistic agent and 5-HT 3 antagonistic agent simultaneously, in sequence or at an interval.